SCHEMBL5455157

SCHEMBL5455157

CC(C)(C)CC(=O)Nc1sc2c(c1C(N)=O)CCOC2

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 7/20 0.69
CFTR P13569 1/20 0.59
KDM4E B2RXH2 2/20 0.51
PTPRC P08575 1/20 0.51
PTPN2 P17706 1/20 0.51
PTPN1 P18031 1/20 0.51
PTPRB P23467 1/20 0.51
PTPRE P23469 1/20 0.51
FLT3 P36888 1/20 0.51
MAPK1 P28482 1/20 0.51
CNR1 P21554 4/20 0.49
ANO1 Q5XXA6 3/20 0.49
ALDH1A1 P00352 4/20 0.49
ALOX15 P16050 1/20 0.49
HSD17B10 Q99714 1/20 0.49
MEN1 O00255 1/20 0.47
RAB9A P51151 1/20 0.47
MAPK10 P53779 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5460139 0.84 CFTR (0.60) CNR2CFTRKDM4EPTPRCPTPN2
SCHEMBL5445049 0.84 CFTR (0.60) CNR2CFTRKDM4EPTPRCPTPN2
SCHEMBL5467520 0.84 ANO1 (0.67) CNR2CFTRKDM4EPTPRCPTPN2
SCHEMBL5467138 0.83 CFTR (0.62) CNR2CFTRKDM4EPTPRCPTPN2
SCHEMBL8288772 0.83 KDM4E (0.74) CNR2KDM4EFLT3MAPK1CNR1
SCHEMBL8288674 0.83 FLT3 (0.74) CNR2KDM4EFLT3MAPK1CNR1
SCHEMBL5451710 0.82 CFTR (0.58) CNR2CFTRKDM4EPTPRCPTPN2
SCHEMBL8290653 0.82 CFTR (0.67) CNR2CFTRKDM4EPTPRCPTPN2
SCHEMBL5449075 0.82 CFTR (0.66) CNR2CFTRKDM4EPTPRCPTPN2
SCHEMBL5453289 0.82 LMNA (0.59) CNR2CFTRKDM4EPTPRCPTPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CNR2 2272/4885CFTR 2030/4885KDM4E 3417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.